1. Home
  2. RSF vs CNTX Comparison

RSF vs CNTX Comparison

Compare RSF & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RSF
  • CNTX
  • Stock Information
  • Founded
  • RSF 2016
  • CNTX 2015
  • Country
  • RSF United States
  • CNTX United States
  • Employees
  • RSF N/A
  • CNTX N/A
  • Industry
  • RSF Investment Managers
  • CNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • RSF Finance
  • CNTX Health Care
  • Exchange
  • RSF Nasdaq
  • CNTX Nasdaq
  • Market Cap
  • RSF N/A
  • CNTX 76.5M
  • IPO Year
  • RSF N/A
  • CNTX 2021
  • Fundamental
  • Price
  • RSF $15.35
  • CNTX $1.14
  • Analyst Decision
  • RSF
  • CNTX Strong Buy
  • Analyst Count
  • RSF 0
  • CNTX 4
  • Target Price
  • RSF N/A
  • CNTX $7.38
  • AVG Volume (30 Days)
  • RSF 11.8K
  • CNTX 956.9K
  • Earning Date
  • RSF 01-01-0001
  • CNTX 11-06-2024
  • Dividend Yield
  • RSF 10.61%
  • CNTX N/A
  • EPS Growth
  • RSF N/A
  • CNTX N/A
  • EPS
  • RSF N/A
  • CNTX N/A
  • Revenue
  • RSF N/A
  • CNTX N/A
  • Revenue This Year
  • RSF N/A
  • CNTX N/A
  • Revenue Next Year
  • RSF N/A
  • CNTX N/A
  • P/E Ratio
  • RSF N/A
  • CNTX N/A
  • Revenue Growth
  • RSF N/A
  • CNTX N/A
  • 52 Week Low
  • RSF $14.81
  • CNTX $0.89
  • 52 Week High
  • RSF $16.23
  • CNTX $2.75
  • Technical
  • Relative Strength Index (RSI)
  • RSF 50.78
  • CNTX 31.94
  • Support Level
  • RSF $15.04
  • CNTX $0.94
  • Resistance Level
  • RSF $15.44
  • CNTX $1.20
  • Average True Range (ATR)
  • RSF 0.16
  • CNTX 0.13
  • MACD
  • RSF -0.02
  • CNTX -0.02
  • Stochastic Oscillator
  • RSF 54.39
  • CNTX 28.25

About CNTX Context Therapeutics Inc.

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Share on Social Networks: